Biosimilars for Retinal Diseases: An Update - 14/04/21
, Nilesh Kumar a, Nikulaa Parachuri a, Francesco Bandello b, Baruch D. Kuppermann c, Anat Loewenstein dAbstract |
Purpose |
To review the biosimilars of anti–vascular endothelial growth factor agents for retinal diseases and provide an update about their development.
Design |
Literature review.
Methods |
A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology.
Results |
To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results.
Conclusion |
Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions.
Le texte complet de cet article est disponible en PDF.Plan
Vol 224
P. 36-42 - avril 2021 Retour au numéro
Article précédent
- COVID-19 and the Unfinished Agenda of VISION 2020
- Lawson Ung, Jost B. Jonas, Thomas M. Lietman, James Chodosh
- The Tube Versus Trabeculectomy IRIS® Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial
- Elizabeth A. Vanner, Catherine Q. Sun, Matthew J. McSoley, Patrice J. Persad, William J. Feuer, Flora Lum, Scott P. Kelly, Richard K. Parrish, Ta C. Chang, Steven J. Gedde
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?